Skip to main content

Table 5 Population estimate of clearance ( CL ) and steady-state volume of distribution ( V SS ) of antimalarials for a person with a median body weight of 70 kg from mixed effects models from the present study and in previous studies

From: Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients

Drug Subjects Median age (range) [years] No. of patients Duration of sampling CL[L/h] V SS [L] Ref.
AM Patients 10 (1–78) 135 7 days 598 129 Present study
  Patients 22 (14–60) 217 360 h 252a 304a [47]
  Patients 4.0 (1–10) 50 72 h 182–700b 364 [46]
  Patients 7.7 ± 1.4c 13 28 days 102 1263 [48]
  Pregnant women 21 (16–35) 21 10 h 1054d 2602d [49]
DHAe Patients 10 (1–78) 135 7 days 419 129f Present study
  Patients 22 (14–60) 217 360 h 237a 147a [47]
  Pregnant women 21 (16–35) 21 10 h 564 69 [49]
LF Patients 9 (1–78) 143 7 days 7.7 265f Present study
  Patients 22 (14–60) 217 21 301 [47]
  Patients 23 (13–59) 102 7 298 [32]
  Patients 20 (5–66) 309 7.6 361 [32]
  Pregnant women 24 (15–42) 103 336 h 8.7 257 [50]
  Patients 4.0 (1–10) 50 72 h 5.4 623 [46]
  Patients 7.7 ± 1.4c 13 28 days 7.29 506 [48]
DLFg Patients 9 (1–78) 143 7 days 336 265f Present study
  Patients 7.7 ± 1.4c 13 28 days 701 119’500 [48]
MQ Patients 18 (2–57) 63 14 days 2.4 625 Present study
  Patients 14.8 (8–61) 128 28 days 1.4 574.7 [8]
  Patients 9.3 (4–15) 74 28 days 3.71 1,089.2 [8]
  Prophylaxis 26h (18–55) 1,111 26 weeks 1.75 863 [51]
  Patients 19 (2–55) 50 63 days 2.1 767.62 [52]
PPQ Patients 18 (7–53) 60 14 days 109 42,820 Present study
  Patients 3–55 98 63 days 98h 61,180i [53]
  Patients 6 (2–10) 236 42 days 29 14,972 [54]
  Pregnant women 25 (18–43) 24 84 days 90 37,030 [55]
  Non-pregnant women 27.5 (18–45) 24 84 days 92 58,030 [55]
  1. Abbreviations: AM artemether, AS artesunate, DBL desbutyl-lumefantrine, DHA dihydroartemisinin, LF lumefantrine, MQ mefloquine, PPQ piperaquine.
  2. a Fixed parameter at mean value.
  3. b From first to sixth dose.
  4. c Mean ± standard deviation.
  5. d Parameter estimates are weight normalized based on published population mean values divided by the mean weight of subjects.
  6. e Only as metabolite after administration of AM.
  7. f Fixed to Vss of AM.
  8. g Only as metabolite after administration of LF.
  9. h Mean.
  10. i Population estimate for a patient with a median body weight of 48 kg.